PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma

BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. Based on correlative studies regarding the predictive im...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang Kyum, Kim, Jee Hung, Kim, Seung Hyun, Lee, Young Han, Han, Jung Woo, Baek, Wooyeol, Woo, Ha Young, Jeon, Min Kyung, Kim, Hyo Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011221/
https://www.ncbi.nlm.nih.gov/pubmed/33789622
http://dx.doi.org/10.1186/s12885-021-08069-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011221/
https://www.ncbi.nlm.nih.gov/pubmed/33789622
http://dx.doi.org/10.1186/s12885-021-08069-z

Ejemplares similares